Evidence map›Paper›PMID 24772390›Full record

ReviewFrontiers in oncology2014

Marrow Hematopoietic Stem Cells Revisited: They Exist in a Continuum and are Not Defined by Standard Purification Approaches; Then There are the Microvesicles.

Peter J Quesenberry, Laura Goldberg, Jason Aliotta, Mark Dooner

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. The quest of cell surface markers for stem cell therapy.Cellular and molecular life sciences : CMLS · 2021
    Review
  5. Article
  6. Article
  7. Article
  8. Hematopoietic Stem Cells: Uncomfortable Considerations.Current molecular biology reports · 2017
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Peter J QuesenberryDepartment of Medicine, Division of Hematology/Oncology, Rhode Island Hospital , Providence, RI , USA.
Laura GoldbergDepartment of Medicine, Division of Hematology/Oncology, Rhode Island Hospital , Providence, RI , USA.
Jason AliottaDepartment of Medicine, Division of Hematology/Oncology, Rhode Island Hospital , Providence, RI , USA.
Mark DoonerDepartment of Medicine, Division of Hematology/Oncology, Rhode Island Hospital , Providence, RI , USA.

Funding

Stem Cell Biology: New Directions in Clinical and Basic ResearchP20GM103468 · NIGMS · RHODE ISLAND HOSPITAL · PI QUESENBERRY, PETER J. · 2012 to 2013
$4.5M
Genetic information transfer to hematopoietic cells: Role of microvesiclesR01HL103726 · NHLBI · RHODE ISLAND HOSPITAL · PI QUESENBERRY, PETER J. · 2011 to 2014
$1.5M
Regulation of renal and bone marrow injury by extracellular vesicle non-coding RNUH2TR000880 · NCATS · RHODE ISLAND HOSPITAL · PI QUESENBERRY, PETER J. · 2013 to 2014
$498k
NCATS NIH HHS UH2 TR000880NHLBI NIH HHS R01 HL103726NIGMS NIH HHS P20 GM103468
6 · The paper itself

Abstract

Current concepts of hematopoiesis are encompassed in a hierarchical stem cell model. This developed initially from studies of colony-forming unit spleen and in vitro progenitors for different cell lineages, but then evolved into a comprehensive model of cells with different in vivo differentiative and proliferative potential. These cells were characterized and purified based largely on expression of a variety of lineage-specific and stem cell-specific surface epitopes. Monoclonal antibodies were bound to these epitopes and then used to physically and fluorescently separate different classes of these cells. The gold standard for the most primitive marrow stem cells was long-term multilineage repopulation and renewal in lethally irradiated mice. Progressive work seemed to have clonally defined a Lineage negative (Lin-), Sca-1+, c-kit+, CD150+ stem cell with great proliferative, differentiative, and renewal potential. This cell was stable and in the G0 phase of cell cycle. However, continued work in our laboratory indicated that the engraftment, differentiation, homing, and gene expression phenotype of the murine marrow stem cells continuously and reversibly changes with passage through cell cycle. Most recently, using cycle-defining supravital dyes and fluorescent-activated cell sorting and S-phase-specific tritiated thymidine suicide, we have established that the long-term repopulating hematopoietic stem cell is a rapidly proliferating, and thus a continually changing cell; as a corollary it cannot be purified or defined on a clonal single cell basis. Further in vivo studies employing injected and ingested 5-Bromodeoxyuridine (BrdU), showed that the G0 Lin-Sca-1, c-kit+ Flt3- cell was rapidly passing through cell cycle. These data are explained by considering the separative process: the proliferating stem cells are eliminated through the selective separations leaving non-representative dormant G0 stem cells. In other words, they throw out the real stem cells with the purification. This system, where the marrow stem cell continuously and reversibly changes with obligate cell cycle transit, is further complicated by the consideration of the impact of tissue microvesicles on the cell phenotypes. Tissue microvesicles have been found to alter the phenotype of marrow cells, possibly explaining the observations of "stem cell plasticity." These alterations, short-term, are due to transfer of originator cell mRNA and as yet undefined transcription factors. Long-term phenotype change is due to transcriptional modulation; a stable epigenetic change. Thus, the stem cell system is characterized by continuous cycle and microvesicle-related change. The challenge of the future is to define the stem cell population.

Indexed as

cell cyclecircadian rhythmstem cellstem cell purificationvesicles

Identifiers

PMID24772390
PMCPMC3983521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.